Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
作者信息
Zarganes-Tzitzikas Tryfon, Konstantinidou Markella, Gao Yongzhi, Krzemien Dobroslawa, Zak Krzysztof, Dubin Grzegorz, Holak Tad A, Dömling Alexander
机构信息
a Department of Drug Design , University of Groningen , Groningen , The Netherlands.
b Malopolska Centre of Biotechnology , Jagiellonian University , Krakow , Poland.
出版信息
Expert Opin Ther Pat. 2016 Sep;26(9):973-7. doi: 10.1080/13543776.2016.1206527. Epub 2016 Jul 6.
Abstract
摘要
相似文献
1
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
Expert Opin Ther Pat. 2016 Sep;26(9):973-7. doi: 10.1080/13543776.2016.1206527. Epub 2016 Jul 6.
2
Immune checkpoint inhibitors: a patent review (2010-2015).
Expert Opin Ther Pat. 2016 May;26(5):555-64. doi: 10.1080/13543776.2016.1176150. Epub 2016 Apr 18.
3
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Immunotherapy. 2016 May;8(5):583-600. doi: 10.2217/imt-2015-0029.
4
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263.
5
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
6
PD-1/PD-L1 inhibitors.
Curr Opin Pharmacol. 2015 Aug;23:32-8. doi: 10.1016/j.coph.2015.05.011. Epub 2015 Jun 2.
7
Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Cancer J. 2016 Jan-Feb;22(1):17-22. doi: 10.1097/PPO.0000000000000164.
8
Overcoming T cell exhaustion in infection and cancer.
Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18.
9
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Clin Cancer Res. 2012 Dec 15;18(24):6580-7. doi: 10.1158/1078-0432.CCR-12-1362. Epub 2012 Oct 19.
10
PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Cancer Treat Rev. 2015 Dec;41(10):893-903. doi: 10.1016/j.ctrv.2015.09.004. Epub 2015 Sep 21.
引用本文的文献
1
TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies.
Cell Death Dis. 2025 Sep 1;16(1):664. doi: 10.1038/s41419-025-07984-4.
2
Theoretical investigation on PD-L1-In-1 for cancer immunotherapy via density functional theory.
Sci Rep. 2025 Aug 20;15(1):30476. doi: 10.1038/s41598-025-92180-9.
3
Negative Immune Checkpoint Inhibitors.
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
4
Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy.
Int J Nanomedicine. 2025 Jan 8;20:293-308. doi: 10.2147/IJN.S497089. eCollection 2025.
5
Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models.
In Vivo. 2025 Jan-Feb;39(1):80-95. doi: 10.21873/invivo.13805.
6
Miniprotein engineering for inhibition of PD-1/PD-L1 interaction.
Protein Sci. 2024 Aug;33(8):e5106. doi: 10.1002/pro.5106.
7
Molecular glues for protein-protein interactions: Progressing toward a new dream.
Cell Chem Biol. 2024 Jun 20;31(6):1064-1088. doi: 10.1016/j.chembiol.2024.04.002. Epub 2024 May 2.
8
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges.
Front Immunol. 2024 Apr 10;15:1383456. doi: 10.3389/fimmu.2024.1383456. eCollection 2024.
9
Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents.
ACS Omega. 2023 Sep 3;8(37):33242-33254. doi: 10.1021/acsomega.3c00279. eCollection 2023 Sep 19.
10
Antitumor Activity of s-Triazine Derivatives: A Systematic Review.
Molecules. 2023 May 23;28(11):4278. doi: 10.3390/molecules28114278.
本文引用的文献
1
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.
2
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Br J Pharmacol. 2016 May;173(9):1407-24. doi: 10.1111/bph.13450. Epub 2016 Mar 14.
3
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease.
Nat Med. 2016 Feb;22(2):135-7. doi: 10.1038/nm.4022. Epub 2016 Jan 18.
4
Salicylates are interference compounds in TR-FRET assays.
Bioorg Med Chem Lett. 2016 Feb 1;26(3):973-977. doi: 10.1016/j.bmcl.2015.12.050. Epub 2015 Dec 17.
5
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14. doi: 10.1073/pnas.1519623112. Epub 2015 Nov 10.
6
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Structure. 2015 Dec 1;23(12):2341-2348. doi: 10.1016/j.str.2015.09.010. Epub 2015 Oct 22.
7
PD-1 Blockers.
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
8
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy.
Angew Chem Int Ed Engl. 2015 Sep 28;54(40):11760-4. doi: 10.1002/anie.201506225. Epub 2015 Aug 10.
9
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.
10
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
Zotero 插件